Edition:
India

Moleculin Biotech Inc (MBRX.OQ)

MBRX.OQ on NASDAQ Stock Exchange Capital Market

1.71USD
12 Dec 2017
Change (% chg)

$-0.06 (-3.39%)
Prev Close
$1.77
Open
$1.76
Day's High
$1.77
Day's Low
$1.70
Volume
23,131
Avg. Vol
88,695
52-wk High
$3.74
52-wk Low
$0.71

Chart for

About

Moleculin Biotech, Inc. is a preclinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML).... (more)
No analyst recommendations are available for .

Overall

Beta: --
Market Cap(Mil.): $49.84
Shares Outstanding(Mil.): 20.26
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Moleculin Biotech Says Co Was Informed That Investigational NDA For Phase I Trial Of WP1066 Has Been Allowed By FDA

* MOLECULIN BIOTECH SAYS ON NOV 29, CO WAS INFORMED THAT INVESTIGATIONAL NDA FOR PHASE I TRIAL OF WP1066 HAS BEEN ALLOWED BY FDA - SEC FILING Source text: [http://bit.ly/2jcVpeo] Further company coverage:

04 Dec 2017

BRIEF-Moleculin Biotech Q3 loss per share $0.14‍​

* Moleculin Biotech Inc reports financial results for the third quarter ended september 30, 2017

14 Nov 2017

BRIEF-Moleculin appoints Sandra Silberman as chief medical officer

* Moleculin appoints Dr. Sandra Silberman as chief medical officer -- new products Source text for Eikon: Further company coverage:

08 Nov 2017

BRIEF-Moleculin announces MD Anderson has filed an IND with the FDA on its drug WP1066 for the treatment of brain tumors

* Moleculin announces MD Anderson has filed an IND with the FDA on its drug WP1066 for the treatment of brain tumors

01 Nov 2017

BRIEF-Moleculin requests for clinical trial authorization to study annamycin

* Moleculin Biotech - ‍submitted request for clinical trial authorization to study annamycin for treating relapsed/refractory acute myeloid leukemia in Poland Source text for Eikon: Further company coverage:

24 Oct 2017

BRIEF-Moleculin announces strategic collaboration to develop immune stimulation drug

* Moleculin announces strategic collaboration to develop immune stimulation drug

11 Oct 2017

BRIEF-Moleculin announces FDA approval of Annamycin IND

* Moleculin Biotech - ‍U.S. IND allows Moleculin to make submission to Polish authorities for planned Annamycin clinical trial to be conducted in Poland​ Source text for Eikon: Further company coverage:

26 Sep 2017

BRIEF-Moleculin engages CRO to begin clinical trials of WP1220 for the treatment of cutaneous T-Cell lymphoma

* Moleculin engages CRO to begin clinical trials of WP1220 for the treatment of cutaneous T-Cell lymphoma

13 Sep 2017

BRIEF-Moleculin to combine brain cancer drug candidate with Roche's Avastin

* Moleculin to collaborate on combining its WP1122 brain cancer drug candidate with Roche's drug Avastin

06 Sep 2017

BRIEF-Moleculin announces filing with FDA of IND for its leukemia drug Annamycin

* Moleculin announces filing with FDA of IND for its leukemia drug Annamycin

29 Aug 2017

Earnings vs. Estimates